aTyr Pharma, Inc. (LIFE) Receives $3.83 Average Price Target from Brokerages

aTyr Pharma, Inc. (NASDAQ:LIFE) has earned a consensus rating of “Hold” from the six research firms that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and one has issued a buy recommendation on the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $5.00.

Several brokerages have issued reports on LIFE. ValuEngine lowered aTyr Pharma from a “sell” rating to a “strong sell” rating in a report on Wednesday. Zacks Investment Research upgraded aTyr Pharma from a “hold” rating to a “buy” rating and set a $3.50 price target on the stock in a report on Wednesday. BMO Capital Markets set a $4.00 price target on aTyr Pharma and gave the stock a “hold” rating in a report on Tuesday, August 15th. Finally, Piper Jaffray Companies began coverage on aTyr Pharma in a report on Thursday. They issued an “overweight” rating and a $7.00 price target on the stock.

ILLEGAL ACTIVITY WARNING: This article was originally published by TrueBlueTribune and is the property of of TrueBlueTribune. If you are viewing this article on another publication, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this article can be accessed at https://www.truebluetribune.com/2017/09/17/atyr-pharma-inc-life-receives-3-83-average-price-target-from-brokerages.html.

aTyr Pharma (LIFE) traded up 3.28% during midday trading on Thursday, hitting $3.15. The stock had a trading volume of 94,347 shares. The company’s 50 day moving average price is $3.04 and its 200-day moving average price is $3.31. The stock’s market capitalization is $75.09 million. aTyr Pharma has a 52 week low of $2.10 and a 52 week high of $4.45.

aTyr Pharma (NASDAQ:LIFE) last announced its earnings results on Monday, August 14th. The biotechnology company reported ($0.51) EPS for the quarter, beating the consensus estimate of ($0.57) by $0.06. Equities analysts anticipate that aTyr Pharma will post ($2.18) earnings per share for the current fiscal year.

In related news, CEO John Mendlein acquired 37,736 shares of the stock in a transaction dated Thursday, August 31st. The stock was purchased at an average cost of $2.65 per share, with a total value of $100,000.40. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Paul Schimmel acquired 94,336 shares of the stock in a transaction dated Thursday, August 31st. The stock was bought at an average cost of $2.65 per share, with a total value of $249,990.40. Following the completion of the purchase, the director now owns 40,440 shares of the company’s stock, valued at $107,166. The disclosure for this purchase can be found here. 33.30% of the stock is currently owned by corporate insiders.

A hedge fund recently raised its stake in aTyr Pharma stock. Renaissance Technologies LLC raised its stake in aTyr Pharma, Inc. (NASDAQ:LIFE) by 1.8% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 38,800 shares of the biotechnology company’s stock after purchasing an additional 700 shares during the quarter. Renaissance Technologies LLC owned 0.16% of aTyr Pharma worth $136,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 46.66% of the company’s stock.

About aTyr Pharma

aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.

Receive News & Ratings for aTyr Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply